Integra LifeSciences Reports Interim Q4 Sales Marginally Ahead Of Expectations

Integra LifeSciences Holdings Corp IART expects Q4 FY21 sales of $404 million - $406 million, representing an increase of approximately 4% Y/Y on a reported basis and 8% on an organic basis.

  • Interim Q4 sales beat the consensus of $403.9 million.
  • In its Q3 earnings report, the company targeted Q4 revenue of $403 million, representing reported growth of 3.5% and organic growth of 6.5%.
  • The company expects FY21 sales of $1.541 billion - $1.543 billion (consensus $1.54 billion), +12% Y/Y on a reported basis, and 14% organic. In its Q3 report, the company reaffirmed its previous FY21 revenue guidance of $1.540 billion - $1.550 billion, with an expectation to be at the low end of the range.
  • "We remain committed to achieving our 5% - 7% long-term organic growth target and are reaffirming our long-term financial aspirations," said Jan De Witte, Integra's President & CEO.
  • The company plans a $125 million share repurchase as part of a previous approval with authorization of up to $225 million.
  • Price Action: IART shares closed 0.72% higher at $67.18 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareBuybacksGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!